Prolynxinc
Founded 2009 · 39 employees on LinkedIn · 2 known investors
Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals. Its lead program, PLX-821 (semaglutide), and broader pipeline of dual/triple agonists, amylin-based, and combination therapies are built on this half-life extension delivery architecture.
Founders & leadership
Prolynxinc was founded in 2009 by Gary Ashley and Daniel Santi.
Investors · 2
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $245.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $149.6K |
| National Science Foundation | Phase II | 2015 | $742.8K |
| National Science Foundation | Phase I | 2013 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $149.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $144K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Prolynxinc do?
- Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals. Its lead program, PLX-821 (semaglutide), and broader pipeline of dual/triple agonists, amylin-based, and combination therapies are built on this half-life extension delivery architecture.
- Who founded Prolynxinc?
- Prolynxinc was founded by Gary Ashley, Daniel Santi in 2009.
- Who are Prolynxinc's investors?
- Prolynxinc's investors include Monograph Capital Partners, OrbiMed.